Novartis AG $NVS said its lead lung cancer candidate Zykadia showed good results in Phase 3 study. The company now hopes that the results would help it expand regulatory approvals. Nonetheless, it faces a stiff competition from rival Roche, which some analysts say has better treatment intended for the disease. The Swiss pharmaceutical company presented the results of Phase 3 clinical study of Zykadia or ceritinib, on previously untreated patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients when treated with Zykadia showed a substantial progress in their chances of surviving without the cancer spreading compared with standard chemotherapy.